CTT begins Phase I trial of CTT1057 to treat men with high-risk metastatic prostate cancer
US-based biotechnology firm Cancer Targeted Technology (CTT) has begun its Phase I clinical trial of CTT1057 in men with high-risk metastatic prostate cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Pharmaceuticals | Prostate Cancer